维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

5篇 您的检索式：作者名="Brian Porter"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis:results from the 52-week,PhaseⅢChina-centric study,MEASURE 5显示文摘Background:Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis(AS)through 5 years in pivotal Phase III studies.Here,we present efficacy and safety results(52-week)of secukinumab in patients with AS from the MEASURE 5 study.Methods:MEASURE 5 was a 52-week,Phase III,China-centric study.Eligible patients were randomly assigned(2:1)to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks(q4w).All placebo patients switched to secukinumab 150 mg q4w starting at Week 16.Primary endpoint was Assessments of SpondyloArthritis international Society(ASAS)20 at Week 16.Randomization was stratified by region(China vs.non-China).Results:Of 458 patients(secukinumab 150 mg,N=305;placebo,N=153)randomized,327(71.4%)were from China and 131(28.6%)were not from China.Of these,97.7%and 97.4%patients completed Week 16 and 91.1%and 95.3%(placebo-secukinumab)patients completed Week 52 of treatment.The primary endpoint was met;secukinumab significantly improved ASAS20 response at Week 16 vs.placebo(58.4%vs.36.6%;P<0.0001);corresponding rate in the Chinese population was 56.0%vs.38.5%(P<0.01).All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16;responses were maintained with a trend toward increased efficacy from Week 16 to 52.No new or unexpected safety signals were reported up to Week 52.Conclusions:Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS.Secukinumab was well tolerated and the safety profile was consistent with previous reports.Efficacy and safety results were comparable between the overall and Chinese populations.	Feng Huang Fei Sun Wei-Guo Wan Li-Jun Wu Ling-Li Dong Xiao Zhang Tae-Hwan Kim Raj Sengupta Ladislav Senolt Yi Wang Hao-Min Qiu Brian Porter Sibylle Haemmerle	2020	Chinese Medical Journal2020，，21：	2
	2	Robot-Assisted Partial Nephrectomy: An International Experience显示文摘	Brian M. Benway Sam B. Bhayani Craig G. Rogers James R. Porter Nicolò M. Buffi Robert S. Figenshau Alexandre Mottrie	2010	European Urology2010，，5：	1
	3	Woody vegetation and canopy fragmentation along a forest-to-urban gradient显示文摘	Eric E. Porter Brian R. Forschner Robert B. Blair	2001	Urban Ecosystems2001，，2：	1
	4	Robot-Assisted Partial Nephrectomy: An International Experience显示文摘	Brian M. Benway Sam B. Bhayani Craig G. Rogers James R. Porter Nicolò M. Buffi Robert S. Figenshau Alexandre Mottrie	2010	European Urology2010，，5：	1
	5	Assessing the integrity of field devices in modbus networks显示文摘	Ryan Shayto Brian Porter Rodrigo Chandia	2009	Interna-tional Federation for Information Processing2009，290，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费